One thing we could say about the analysts on Ginkgo Bioworks Holdings, Inc.( NYSE:DNA ) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
Following the latest downgrade, the current consensus, from the three analysts covering Ginkgo Bioworks Holdings, is for revenues of US$123m in 2026, which would reflect a considerable 19% reduction in Ginkgo Bioworks Holdings' sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$159m in 2026. It looks like forecasts have become a fair bit less optimistic on Ginkgo Bioworks Holdings, given the pretty serious reduction to revenue estimates.
View our latest analysis for Ginkgo Bioworks Holdings
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. Over the past five years, revenues have declined around 10% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for an annualised 24% decline in revenue until the end of 2026. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 6.7% annually. So while a broad number of companies are forecast to grow, unfortunately Ginkgo Bioworks Holdings is expected to see its sales affected worse than other companies in the industry.
The Bottom Line
The clear low-light was that analysts slashing their revenue forecasts for Ginkgo Bioworks Holdings this year. They're also anticipating slower revenue growth than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on Ginkgo Bioworks Holdings after today.
Unanswered questions? At least one of Ginkgo Bioworks Holdings' three analysts has provided estimates out to 2027, which can be seen for free on our platform here.
Another way to search for interesting companies that could be reaching an inflection pointis to track whether management are buying or selling, with our free list of growing companies backed by insiders .
Have feedback on this article? Concerned about the content? Get in touch
with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
